PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that Phase 2 clinical data for its lead product candidate D-PLEX₁₀₀ will be presented at the Midwest Surgical Association 2022 Annual Meeting on August 8, 2022. This podium presentation, titled Reduction in Surgical Site Infections by Localized Administration with D-PLEX₁₀₀ in Patients with Multiple Risk Factors Undergoing Colorectal Surgery, will be given by Senior Medical Director Dr. Anthony J. Senagore. D-PLEX₁₀₀ aims to prevent infections post-abdominal surgery.

Positive

• Phase 2 clinical data for D-PLEX100 shows promising results in preventing surgical site infections.
• The upcoming presentation at a notable conference can enhance visibility and investor interest in PYPD.

Negative

• None.

Efficacy Data of D-PLEX₁₀₀ in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation

PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) --  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX₁₀₀ will be highlighted in a podium presentation at the Midwest Surgical Association 2022 Annual Meeting being held on August 7-9, 2022, at the Grand Hotel in Mackinac Island, Michigan.

Midwest Surgical Association 2022 Annual Meeting:

Presentation Title:	Reduction in Surgical Site Infections by Localized Administration with D-PLEX100 in Patients with Multiple Risk Factors Undergoing Colorectal Surgery
Presenter:	Anthony J. Senagore, M.D., Senior Medical Director of PolyPid
Date/Time:	Monday, August 8, 2022, Scientific Session I, 8:15 a.m. – 8:30 a.m.

The presentation will be available on http://www.polypid.com/ following its conclusion.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com 

 

FAQ

What is the purpose of the D-PLEX100 Phase 2 clinical trial?

The Phase 2 clinical trial for D-PLEX100 aims to evaluate its efficacy in preventing surgical site infections in high-risk patients undergoing colorectal surgery.

When will the D-PLEX100 clinical trial results be presented?

The results will be presented on August 8, 2022, at the Midwest Surgical Association 2022 Annual Meeting.

Who is presenting the D-PLEX100 trial data at the conference?

Dr. Anthony J. Senagore, Senior Medical Director of PolyPid, will present the D-PLEX100 trial data.

What is the potential market impact of D-PLEX100?

If proven effective, D-PLEX100 could significantly reduce surgical site infections, potentially improving surgical outcomes and increasing market demand for PolyPid's products.